Table 2.
Cut Pointsng/mg Cr | Remission failure % | Unadjusted OR (95% Cl); P | Adjusted OR (95% Cl) | |||
---|---|---|---|---|---|---|
Model 1 a , P | Model 2 b , P | Model 3 c , P | ||||
Urinary sCD163 | ||||||
T1+T2 (n=175) | ≤3.57 | 14.3 | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) |
T3 (n=87) | >3.57 | 37.9 | 3.67 (2.00-6.72); <0.0001 | 3.91 (2.06-7.41); <0.0001 | 2.32 (1.09-4.90); 0.028 | 2.66 (1.22-5.86); 0.014 |
Urinary IL6 | ||||||
T1+T2 (n=175) | ≤52.36 | 17.1 | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) |
T3 (n=87) | >52.36 | 32.6 | 2.28 (1.26-4.12); 0.007 | 2.33 (1.25-4.37); 0.008 | 1.99 (1.03-3.88); 0.042 | 2.06 (1.05-4.03); 0.035 |
Urinary MCP-1 | ||||||
T1+T2 (n=175) | ≤542.48 | 17.2 | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) |
T3 (n=87) | >542.48 | 32.2 | 2.28 (1.26-4.12); 0.007 | 2.49 (1.31-4.73); 0.006 | 1.69 (0.84-3.38); 0.140 | 1.72 (0.85-3.47); 0.130 |
Cl, confidence interval; Cr, creatinine; OR, Odds ratio; MCP-1, monocyte chemoattractant protein-1; BMI, body mass index; eGFR, estimated glomerular filtration rate; MAP, mean arterial blood pressure; MEST-C, histologic score based on mesangial hypercellularity, the presence of endocapillary proliferation, segmental glomerulosclerosis/adhesion, and severity of tubular atrophy/interstitial fibrosis, and crescents formation; T, tertile.
Model 1 adjusted for age, sex, MAP, BMI.
Model 2 adjusted for covariates in model 1 plus 24-hour proteinuria, eGFR and Oxford MEST-C score.
Model 3 adjusted for covariates in model 1 and 2 plus use of renin-angiotensin system inhibition and immunosuppression during follow-up.